Wird geladen...
Pharmacokinetics of Gepotidacin in Subjects With Normal Hepatic Function and Hepatic Impairment
Gepotidacin is a novel triazaacenaphthylene bacterial topoisomerase inhibitor. This phase 1 nonrandomized, open‐label, multicenter, 2‐part study evaluated the pharmacokinetics, safety, and tolerability of oral gepotidacin 1500 mg in 3 different hepatic settings (normal, moderate impairment, and seve...
Gespeichert in:
| Veröffentlicht in: | Clin Pharmacol Drug Dev |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
John Wiley and Sons Inc.
2021
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8248074/ https://ncbi.nlm.nih.gov/pubmed/33450142 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpdd.913 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|